Moving at the Speed of Science

Our Science
NoShortcutsStill_790X500.jpg
NoShortcutsStill_1000X450.jpg

Moving at the Speed of Science

An open letter from our Chairman and CEO on working together to build trust in science.

COVID-19 INFORMATION AND RESOURCES

Your Health
man_lab_dark_380x500.png
man_lab_dark_1000x450_0.jpg

COVID-19 INFORMATION AND RESOURCES

Current information on our scientific progress to bring forward a safe and effective vaccine to help protect against the novel coronavirus.

COVID-19 Vaccine Development

Our Science
woman_holding_vial_380X500.jpg
woman_holding_vial_1000X450.jpg

COVID-19 Vaccine Development

Rapid progress on the path to develop, test and manufacture a vaccine.

STEPS FOR MANAGING FINANCES AND HEALTH INSURANCE AFTER A CANCER DIAGNOSIS

Your Health
Managing_Finances_After_Cancer_Diagnosis_790X500
Managing_Finances_After_Cancer_Diagnosis_1000x450.jpg

STEPS FOR MANAGING FINANCES AND HEALTH INSURANCE AFTER A CANCER DIAGNOSIS

Cost should never be a barrier to receiving cancer treatment, yet there are people who forgo treatment so as not to burden their family with high medical costs.

Find a Trial

Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your city or zip code to find studies near you.

THE ANTIGEN: #COVID19 PODCAST

Podcasts
the_antigen_image_380x700.png
the_antigen_image_1000x450.jpg

THE ANTIGEN: #COVID19 PODCAST

Season 2 of The Antigen podcast focuses on COVID-19, Pfizer’s response to the crisis and more.

Maintaining Positivity: A Mother and Daughter’s Perspective on Chronic Pain Due to Osteoarthritis

Your Health
Maintaining_Positivity_790x500.png
Maintaining_Positivity_1000x450.jpg

Maintaining Positivity: A Mother and Daughter’s Perspective on Chronic Pain Due to Osteoarthritis

In recognition of Pain Awareness Month, Ann and her daughter Elizabeth (Lizzie) Sullivan sat down with Grace Whiting, President & CEO of the National Alliance for Caregiving, to discuss the impact that chronic pain due to OA can have.

Latest News

The German Breast Group (GBG) and Pfizer Inc. (NYSE: PFE) today announced that the collaborative Phase 3 PENELOPE-B trial did not meet the primary endpoint of improved invasive disease-free survival (iDFS) in women with hormone receptor-positive (HR+), human epidermal growth factor-negative (HER2-) early breast cancer (eBC) who have residual invasive disease after completing neoadjuvant chemotherapy. No unexpected safety signals were observed. This press release features multimedia. View the…